The Food and Drug Administration (FDA) has approved 2 additional vial sizes of Niktimvo ™ (axatilimab-csfr), 9mg/0.18mL and 22mg/0.44mL, in addition to the 50mg/mL size.

A phase 3 trial of MaaT Pharma’s graft-versus-host disease (GvHD) drug candidate has hit its primary endpoint, positioning ...

A YOUNG mum battling a rare form of cancer passed away surrounded by loved ones after suffering complications from treatment.

Niktimvo marks the first FDA-approved therapy targeting CSF-1R to address inflammation and fibrosis in chronic ...

Axatilimab has gained FDA approval in 9 mg and 22 mg vials, expanding treatment options for patients with chronic GVHD after ...

The regulator has cleared Ryoncil (remestemcel-L) to treat steroid-refractory acute GVHD in paediatric patients aged two months and older. It is derived from MSCs harvested from the bone marrow of ...

The FDA has approved Incyte's axatilimab as a treatment for chronic graft-versus-host disease (GvHD), making it a companion to the company's Jakafi for the disorder. The US regulator has cleared ...

GVHD is a complication that might occur after a cell transplant, where the donated stem cells attack the recipient’s cells, viewing them as an unfamiliar threat. Mesenchymal stromal cells are ...

Incyte (Nasdaq:INCY) and Syndax Pharmaceuticals (Nasdaq:SNDX) today announced that the U.S. Food and Drug Administration (FDA) has approved Niktimvo™ (axatilimab-csfr) in 9 mg and 22 mg vial sizes.

A transplant using your own stem cells is called an autograft or autologous transplant. GvHD is a possible complication of a transplant from another person. GvHD means the graft reacts against the ...

Symptoms of graft versus host disease (GvHD) depend on the type you have and which parts of your body it affects. There are 2 main types of GVHD. They are: Acute GvHD generally happens within the ...